Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Gemini Therapeutics And Disc Medicine Announce Merger Agreement

Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs Combined company is expected to have approximately $175 million of
byBenzinga Newsdesk
August 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Merger to create NASDAQ-listed, clinical-stage biopharmaceutical company focused on advancing Disc Medicine’s portfolio of hematology programs
  • Combined company is expected to have approximately $175 million of cash or cash equivalents at close, including approximately $53.5 million from a concurrent financing restricted to Disc’s existing investors, and which is expected to provide funding into 2025
  • Transaction will fund multiple clinical studies, including clinical trials of bitopertin for erythropoietic porphyrias, DISC-0974 for anemia of myelofibrosis, and DISC-0974 for anemia of chronic kidney disease
  • Companies will host a joint webcast today, August 10, 2022 at 8:00 a.m. Eastern Time
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Kenon’s Subsidiary OPC Energy Ltd. Announces Agreement by CPV, a subsidiary of OPC, to Acquire Wind Energy Power Plants in the U.S. for $172M

By Charles Gross
January 4, 7:10 AM
Kenon Holdings Ltd.'s (NYSE: KEN, TASE: KEN) ("Kenon") subsidiary OPC Energy Ltd. ("OPC") announced today that OPC's subsidiary, CPV Group LP1 ("CPV"), through a 100% owned subsidiary, has entered into an agreement (the "Agreement") to acquire four operating wind-powered electricity power plants in Maine, United States, with an aggregate capacity of 81.5 MW.

KEN